SVT-40776 in Patients Suffering From Overactive Bladder Syndrome

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00507169

Enrollment

Unknown

Registered

2007-07-26

Start date

2006-09-30

Completion date

2007-09-30

Last updated

2011-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder (OAB)

Brief summary

The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine

Interventions

DRUGSVT-40776

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients suffering from OAB for at least 6 months prior to inclusion

Exclusion criteria

* Pregnant and breastfeeding women * Any medical condition or need for co-medication which interferes with the drug under investigation (SVT-40776) or the comparator (tolterodine)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026